These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7758260)

  • 1. Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects.
    Coates PA; Ismail IS; Luzio SD; Griffiths I; Ollerton RL; Vølund A; Owens DR
    Diabet Med; 1995 Mar; 12(3):235-9. PubMed ID: 7758260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.
    Kipnes M; Dandona P; Tripathy D; Still JG; Kosutic G
    Diabetes Care; 2003 Feb; 26(2):421-6. PubMed ID: 12547873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
    Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of conventional and intensified insulin therapy on free-insulin profiles and glycemic control in NIDDM.
    Lindström TH; Arnqvist HJ; von Schenck HH
    Diabetes Care; 1992 Jan; 15(1):27-34. PubMed ID: 1737539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could intranasal insulin be useful in the treatment of non-insulin-dependent diabetes mellitus?
    Kimmerle R; Griffing G; McCall A; Ruderman NB; Stoltz E; Melby JC
    Diabetes Res Clin Pract; 1991 Aug; 13(1-2):69-75. PubMed ID: 1773716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meal-time intranasal insulin delivery in type 2 diabetes.
    Bruce DG; Chisholm DJ; Storlien LH; Borkman M; Kraegen EW
    Diabet Med; 1991 May; 8(4):366-70. PubMed ID: 1830259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients.
    Scognamiglio R; Negut C; de Kreutzenberg SV; Tiengo A; Avogaro A
    Diabetes Care; 2006 Jan; 29(1):95-100. PubMed ID: 16373903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
    Hermanns N; Burkert A; Haak T
    Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):310-4. PubMed ID: 15216448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
    Gredal C; Rosenfalck A; Dejgaard A; Hilsted J
    Diabetes Res Clin Pract; 2008 May; 80(2):293-8. PubMed ID: 18304675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus.
    Sambol NC; Chiang J; O'Conner M; Liu CY; Lin ET; Goodman AM; Benet LZ; Karam JH
    J Clin Pharmacol; 1996 Nov; 36(11):1012-21. PubMed ID: 8973990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM.
    McMahon M; Marsh HM; Rizza RA
    Diabetes; 1989 Mar; 38(3):291-303. PubMed ID: 2492963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
    Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
    Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
    Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous insulin simulates early insulin peak and reduces post-prandial hyperglycaemia/hyperinsulinaemia in type 2 (non-insulin-dependent) diabetes mellitus.
    Luzio SD; Owens DR; Vora J; Dolben J; Smith H
    Diabetes Res; 1991 Feb; 16(2):63-7. PubMed ID: 1817807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.